BTCY (Biotricity) Cyclically Adjusted Revenue per Share: $0.78 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BTCY Biotricity Inc BTCY
20 GF Score
Price $0.11
GF Value $0.39
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Biotricity Cyclically Adjusted Revenue per Share?

Biotricity BTCY -0.18% 20 Cyclically Adjusted Revenue per Share is $0.78 as of Mar. 2026. GuruFocus rates BTCY with a GF Score™ of 20/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biotricity's adjusted revenue per share for the three months ended in Mar. 2026 was $0.149. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.78 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-19), Biotricity's current stock price is $0.1128. Biotricity's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.78. Biotricity's Cyclically Adjusted PS Ratio of today is 0.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotricity was 1.12. The lowest was 0.14. And the median was 0.51.


Biotricity  (OTCPK:BTCY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biotricity's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.1128/0.78
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotricity was 1.12. The lowest was 0.14. And the median was 0.51.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biotricity Cyclically Adjusted Revenue per Share Related Terms


Biotricity Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biotricity's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotricity Cyclically Adjusted Revenue per Share Chart

Biotricity Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.78 0.78

Biotricity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.78 0.78 0.77 0.78

BTCY vs FEED, LUDG, USAQ: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Biotricity's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotricity Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biotricity's Cyclically Adjusted PS Ratio falls into.


BTCY
20GF Score
Biotricity Inc BTCY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotricity Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biotricity's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.149/330.2130*330.2130
=0.149

Current CPI (Mar. 2026) = 330.2130.

Biotricity Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.003 251.989 0.004
201809 0.016 252.439 0.021
201812 0.021 251.233 0.028
201903 0.031 254.202 0.040
201906 0.055 256.143 0.071
201909 0.058 256.759 0.075
201912 0.063 256.974 0.081
202003 0.060 258.115 0.077
202006 0.074 257.797 0.095
202009 0.120 260.280 0.152
202012 0.161 260.474 0.204
202103 0.183 264.877 0.228
202106 0.271 271.696 0.329
202109 0.253 274.310 0.305
202112 0.236 278.802 0.280
202203 0.255 287.504 0.293
202206 0.240 296.311 0.267
202209 0.275 296.808 0.306
202212 0.283 296.797 0.315
202303 0.314 301.836 0.344
202306 0.345 305.109 0.373
202309 0.329 307.789 0.353
202312 0.331 306.746 0.356
202403 0.337 312.332 0.356
202406 0.226 314.175 0.238
202409 0.145 315.301 0.152
202412 0.149 315.605 0.156
202503 0.141 319.799 0.146
202506 0.147 322.561 0.150
202509 0.145 324.800 0.147
202512 0.145 324.054 0.148
202603 0.149 330.213 0.149

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.78 mean?
Biotricity (BTCY) has a Cyclically Adjusted Revenue per Share of $0.78 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotricity and its competitors.
Is Biotricity's Cyclically Adjusted Revenue per Share too high?
Biotricity's current Cyclically Adjusted Revenue per Share is $0.78. Overall, Biotricity has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotricity's Cyclically Adjusted Revenue per Share compare to FEED and LUDG?
Biotricity's Cyclically Adjusted Revenue per Share of $0.78 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotricity and its competitors. Biotricity's current Cyclically Adjusted Revenue per Share is $0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.11 — trading 71.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.78. Biotricity's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biotricity (BTCY), the current Cyclically Adjusted Revenue per Share is $0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotricity (BTCY) Overvalued in 2026?

Based on GuruFocus' analysis, Biotricity stock appears to be undervalued. The current stock price of $0.11 is trading 71.1% below its estimated GF Value™ of $0.39. GuruFocus considers Biotricity to be Possible Value Trap.

Key valuation signals for BTCY:

  • Cyclically Adjusted Revenue per Share: $0.78
  • GF Value™: $0.39 vs. price of $0.11 (71.1% below fair value)
  • GF Score™: 20/100 with 7 warning signs

No single metric tells the full story. See the BTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biotricity Business Description

Address 203 Redwood Shores Parkway, Suite 600, Redwood City, CA, USA, 94065
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
20GF Score

Get the complete analysis for BTCY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.39
GF Value